Filter News
Area of Research
- (-) Fusion and Fission (2)
- (-) Nuclear Science and Technology (3)
- Advanced Manufacturing (4)
- Biological Systems (1)
- Biology and Environment (11)
- Building Technologies (1)
- Clean Energy (24)
- Climate and Environmental Systems (1)
- Computational Biology (1)
- Computational Engineering (3)
- Computer Science (12)
- Isotopes (11)
- Materials (27)
- Materials for Computing (8)
- Mathematics (1)
- National Security (4)
- Neutron Science (12)
- Quantum information Science (5)
- Supercomputing (43)
News Topics
- (-) Biomedical (1)
- (-) Computer Science (2)
- (-) Isotopes (2)
- (-) Microscopy (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (6)
- Biology (1)
- Chemical Sciences (1)
- Energy Storage (1)
- Environment (1)
- Fusion (9)
- High-Performance Computing (1)
- ITER (4)
- Materials (1)
- Materials Science (2)
- Molten Salt (3)
- Nanotechnology (1)
- Neutron Science (2)
- Nuclear Energy (18)
- Security (1)
- Space Exploration (2)
- Sustainable Energy (1)
- Transportation (1)
Media Contacts
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
Twenty-seven ORNL researchers Zoomed into 11 middle schools across Tennessee during the annual Engineers Week in February. East Tennessee schools throughout Oak Ridge and Roane, Sevier, Blount and Loudon counties participated, with three West Tennessee schools joining in.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.